Clinical trial
Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered…
NCT00158795 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00158795 |
|---|---|
| Title | Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine |
| Official title | Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b Disease |
| Intervention type | Biological |
| Interventions | Haemophilus Influenza type b vaccine |
| Enrollment | 454 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | May 30, 2017 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: